姚志红教授个人简介
姚志红　　
性别:女
籍贯:上海市
民族:汉
党派:群众
职称:教授；博导/硕导
学位:博士
电话: (office); (fax)　　
电子邮件:yaozhihong_jnu@163.com
个人简介：
姚志红，女，博士，暨南大学药学院教授、博士生导师/硕士生导师。2003年1月起入职暨南大学药学院并十六年活跃在教学科研第一线。先后承担了6门本科生中文/全英文课程和2门硕士生课程（负责或主讲）；已经独立培养硕士生14名，协助培养硕士生13人、博士生5人，有3人获国奖、2人校研究生学术创新成果奖、1人校优秀毕业研究生、1人广东省药学优秀研究生学术论文二等奖。近年的研究兴趣围绕中药及复方药效物质揭示，针对仙灵骨葆、栝楼薤白半夏汤、补中益气汤、丹蒌片及薤白、姜等开展中药药代动力学与质量控制研究。主持承担了国家自然科学基金面上项目3项（1项结题/2项在研）、广东省自然科学基金面上项目和科技计划项目等省部级课题4项（3项结题/1项在研）以及厅局级项目2项（均完成）；作为合作方负责人承担了国家重点研发计划子课题1项、作为主要成员参与承担了国家自然科学基金重大国际合作项目和中港合作项目各1项（均完成）、科技部十二五重大新药创制专项2项（均完成）。近五年来，以第一作者 /通讯作者在J. Agric. Food. Chem.,J. Ethnopharmacol.,Food& Funct.,J. Pharm. Biomed. Anal.,Food Chem. 等国际学术期刊发表SCI研究论文25篇（累积影响因子50、单篇最高他引37次，A1区论文4篇）以及中文核心期刊8篇；以第一完成人申请获得中国发明专利授权1项；曾荣获广州市科技进步三等奖1项。
负责或主讲课程:
本科生课程:药物分析;药物分析实验;
药物分析(全英文);药物分析实验(全英文);
现代分析技术;现代分析技术(全英文)。
.研究生课程：中药质量控制方法与技术;
现代药物分析方法。

研究生招生方向：
中药药代及复杂生物样品分析技术（博士招生）
色谱联用技术在药物分析中的应用（硕士招生）

近五年代表性论文（第一作者/通讯作者, 选填10篇）:
[1]Metabolic profiles of ginger, a functional food, and its representative pungent compounds in rats by ultraperformance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. Journal of Agricultural and Food Chemistry, 2018, 66(34): 9010-9033.(Impact factor: 3.412; A1-I; Corresponding author)
[2]Chemical inhibition and stable knock-down of efflux transport leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: The role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides. Food & Function, 2018, 9(3): 1410-1423. (Impact factor: 3.289; A1-Ⅰ; Corresponding author)
[3]Study on chemical profiles and metabolites of Allii Macrostemonis Bulbus as well as its representative steroidal saponins in rats by ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. Food Chemistry, 2016, 192: 499-515.(Impactor factor: 4.946; A1-Ⅱ; ; Corresponding author)
[4]In vivo metabolic profiles of Bu-Zhong-Yi-Qi-Tang, a famous traditional Chinese medicine prescription, in rats by ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis, 2019, 171: 81-98. (Impact factor: 2.983; A2-Ⅲ; Corresponding author)
[5]Simultaneous Quantification of Multiple Representative Components in the Xian-Ling-Gu-Bao Capsule by Ultra-Performance Liquid Chromatography Coupled with Quadrupole Time-of-Flight Tandem Mass Spectrometry. Molecules, 2017, 22(6):1-13. (Impact factor: 3.098; A2-Ⅲ; First author & Corresponding author)
[6]Characterization of human UDP glucuronosyltransferases responsible for glucuronidation and inhibition of norbakuchinic acid, a primary metabolite of hepatotoxicity and nephrotoxicity component bakuchiol in Psoralea corylifolia L. RSC Advances, 2017, 7(83): 52661-52671. (Impact factor: 2.936; A2-Ⅲ; First author & Corresponding author)
[7]Identification, bioactivity evaluation and pharmacokinetics of multiple components in rat serum after oral administration of Xian-Ling-Gu-Bao capsule by ultra performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. Journal of Chromatography B, 2017, 1041: 104-112. (Impact factor: 2.441; A2-Ⅲ;First author & Corresponding author)
[8]In vitroglucuronidation of wushanicaritin by liver microsomes, intestine microsomes and expressed human UDP-Glucuronosyltransferase enzymes. International Journal of Molecular Science, 2017, 18(9): 1-17. (Impactor factor: 3.687; A2-Ⅲ; Corresponding author)
[9]The roles of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated proteins (MRPs/ABCCs) in the excretion of cycloicaritin-3-O-glucoronide in UGT1A1-overexpressing HeLa cells.Chemico-Biological Interactions, 2018, 296, 45-56. (Impact factor: 3.296; A2-Ⅲ;Corresponding author)
[10]Metabolites profile of Xian-Ling-Gu-Bao capsule, a traditional Chinesemedicine prescription, in rats by ultra performance liquidchromatography coupled with quadrupole time-of-flight tandemmass spectrometry analysis. Journal of Pharmaceutical and Biomedical Analysis, 2014, 96: 90–103. (Impact factor: 2.831; A2-Ⅲ;Corresponding author)